According to India’s state owned Pharmaceutical Export Promotion Council’s year-end report, pharma exports from the country are expected to reach $19.1 billion during the current fiscal year — despite muted growth in the North American markets — a growth of 10.72 percent over $17.28 billion in pharma exports last year.
Pharmaceuticals Export Promotion Council’s director general Uday Bhaskar said that most of the issues that the United States Food and Drug Administration had flagged and which had impacted exports from India in the first five months of the last fiscal, were getting resolved. “The Chinese market is also opening up. We are working on that. China has removed tariff on certain cancer drugs. All these create a conducive atmosphere for India’s drug exporters,” he said.
Of the total 1638 market authorizations granted by the U.S. Food and Drug Administration in 2018, Indian companies were awarded 538 authorizations (product approvals) and many of these products have six or more companies competing to export them. “Indian companies need to file complex generic applications as also file applications for bio-similars to steer away from intense competition and look for higher margins,” the report added.
Last updated: December 26th, 2025
